Leber’s Hereditary Optic Neuropathy (LHON) Market: Analysis of Evolving Epidemiology Trends, Pipeline Therapies, and Key Companies-Stealth BioTherapeutics, Santhera Pharmaceuticals GenSight Biologica

Leber's Hereditary Optic Neuropathy (LHON)  Market: Analysis of Evolving Epidemiology Trends, Pipeline Therapies, and Key Companies-Stealth BioTherapeutics, Santhera Pharmaceuticals GenSight Biologica
DelveInsight Business Research LLP
DelveInsight’s “Leber’s Hereditary Optic Neuropathy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Leber’s Hereditary Optic Neuropathy, historical and forecasted epidemiology as well as the Leber’s Hereditary Optic Neuropathy market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s “Leber’s Hereditary Optic Neuropathy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Leber’s Hereditary Optic Neuropathy, historical and forecasted epidemiology as well as the Leber’s Hereditary Optic Neuropathy market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Leber’s Hereditary Optic Neuropathy Market Overview

Leber’s Hereditary Optic Neuropathy is a mitochondrially inherited (transmitted from mother to offspring) degeneration of retinal ganglion cells (RGCs) and their axons that leads to an acute or subacute loss of central vision; it predominantly affects young adult males. Leber’s Hereditary Optic Neuropathy is transmitted only through the mother, as it is primarily due to mutations in the mitochondrial (not nuclear) genome, and only the egg contributes mitochondria to the embryo. Leber’s Hereditary Optic Neuropathy is usually due to one of three pathogenic mitochondrial DNA (mtDNA) point mutations. These mutations are at nucleotide positions 11778 G to A, 3460 G to A, and 14484 T to C, respectively in the ND4, ND1, and ND6 subunit genes of complex I of the oxidative phosphorylation chain in mitochondria. Men cannot pass on the disease to their offspring

Leber’s Hereditary Optic Neuropathy Market Epidemiological Insights:

  • In Northern European populations about one in 9,000, people carry one of the three primary Leber’s Hereditary Optic Neuropathy mutations. There is a prevalence of between 1:30,000 to 1:50,000 in Europe.

  • Leber’s Hereditary Optic Neuropathy  ND4 G11778A mutation is the primary mutation in most of the world, with 70% of Northern European cases and 90% of Asian cases. Due to a Founder effect, the ND6 T14484C mutation accounts for 86% of Leber’s Hereditary Optic Neuropathy cases in Quebec, CanadaMore than 50% of males with a mutation and more than 85% of females with a mutation never experience vision loss or related medical problems. The particular mutation type may predict the likelihood of penetrance, the severity of illness, and the probability of vision recovery in the affected. As a rule of thumb, a woman who harbors a homoplasmic primary mutation has a ~40% risk of having an affected son and a ~10% risk of having an affected daughter

 

Leber’s Hereditary Optic Neuropathy Market Epidemiological Segmentation 

  • Leber’s Hereditary Optic Neuropathy incident cases. 

  • Leber’s Hereditary Optic Neuropathy treated cases. 

  • Leber’s Hereditary Optic Neuropathy diagnosed cases. 

 

Leber’s Hereditary Optic Neuropathy  Market Outlook 

The Leber’s Hereditary Optic Neuropathy market outlook of the report helps to build a detailed comprehension of the historical, current and forecasted Leber’s Hereditary Optic Neuropathy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

 

This segment gives a thorough detail of the Leber’s Hereditary Optic Neuropathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. 

 

According to DelveInsight, the Leber’s Hereditary Optic Neuropathy market in 7MM is expected to witness a major change during the study period 2019-2032.

 

Key Companies in the Leber’s Hereditary Optic Neuropathy  Market Include:

  • Stealth BioTherapeutics 

  • Santhera Pharmaceuticals 

  • GenSight Biologicals 

  • Quark Pharmaceuticals 

And many others 

Leber’s Hereditary Optic Neuropathy  Therapies Covered and Analyzed in the Report:

  • Elamipretide (MTP-131) 

  • Idebenone

  • GS010

  • Idebenone 

And many others 

Learn more about Leber’s Hereditary Optic Neuropathy  Emerging Therapies and Key Companies

Table of Contents

  1.  Key Insights 

  2.  Leber’s Hereditary Optic Neuropathy  Report Introduction 

  3.  Executive Summary of the Leber’s Hereditary Optic Neuropathy Market  

  4.  Leber’s Hereditary Optic Neuropathy Disease Background and Overview

  5.  Leber’s Hereditary Optic Neuropathy Epidemiology and patient population

  6.  Leber’s Hereditary Optic Neuropathy Market Emerging Therapies

  7.  Leber’s Hereditary Optic Neuropathy Market Drivers 

  8.  Leber’s Hereditary Optic Neuropathy Market Barriers 

  9.  Market Access and Reimbursement of Therapies

  10.  Appendix

  11.  Leber’s Hereditary Optic Neuropathy Market Report Methodology

  12.  DelveInsight Capabilities

  13.  Disclaimer

  14.  About DelveInsight

Learn more about the detailed offering of the report:  Leber’s Hereditary Optic Neuropathy  Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services